The present invention relates to the field of diagnostics and more particularly to the detection of beta-hemolytic pathogens. More specifically, the present invention relates to the rapid and accurate detection of beta-hemolytic pathogens using sterically-stabilized liposomes.

The present invention relates to the field of diagnostics and more particularly to the detection of beta-hemolytic pathogens. More specifically, the present invention relates to the rapid and accurate detection of beta-hemolytic pathogens using sterically-stabilized liposomes.

Disclosed herein is an engineered bacteriophage comprising an indicator gene, wherein said indicator gene is an RNA aptamer or a green fluorescent protein (GFP) or GFP-like protein, and further wherein said indicator gene can indicate the presence of a microorganism, such as a bacterial infection. The engineered bacteriophage can be capable of infecting and killing the microorganism. The engineered microorganism can be in a composition for delivery to a subject, and can be in hyaluronic acid, for example. Also disclosed are methods of using the engineered bacteriophage to diagnose and/or treat a subject with a bacterial infection.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1.fwdarw.3) glucose 2 (1.fwdarw.3) rhamnose (1.fwdarw.3) ribitol (5.fwdarw.phosphate}. This new serotype may be included in pneumococcal vaccines.

Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {2) glucose 1 (1.fwdarw.3) glucose 2 (1.fwdarw.3) rhamnose (1.fwdarw.3) ribitol (5.fwdarw.phosphate}. This new serotype may be included in pneumococcal vaccines.

A bacteria-responsive color-changing, core-shell nanofiber, comprising polyurethane (PU), a hemicyanine-based chromogenic probe localized in the core-shell nanofiber near the surface of the shell, polyvinylpyrrolidone (PVP) dopant in the shell, the hemicyanine-based chromogenic probe further comprising a labile ester linkage that is enzymatically cleavable by bacterial lipase released from clinically relevant strains of bacteria including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).

One aspect of the present disclosure relates to a device for detecting a target analyte in a liquid sample. The device can comprise a housing. The housing can include an inlet for receiving a liquid sample, an outlet for removing a volume of the liquid sample from the device, a filter associated with the outlet and being sized and dimensioned to retain a target analyte on a surface thereof, and a flow system comprising at least one channel that is in communication with the inlet and the outlet. At least a portion of the at least one channel can be located substantially adjacent the surface of the filter and be shaped and dimensioned to reduce the amount of unreacted fluorescent probe available to create the background interference during detection of the target analyte.

One aspect of the present disclosure relates to a device for detecting a target analyte in a liquid sample. The device can comprise a housing. The housing can include an inlet for receiving a liquid sample, an outlet for removing a volume of the liquid sample from the device, a filter associated with the outlet and being sized and dimensioned to retain a target analyte on a surface thereof, and a flow system comprising at least one channel that is in communication with the inlet and the outlet. At least a portion of the at least one channel can be located substantially adjacent the surface of the filter and be shaped and dimensioned to reduce the amount of unreacted fluorescent probe available to create the background interference during detection of the target analyte.

An analysis method includes: acquiring data corresponding to a mass spectrum obtained by subjecting a sample containing a microorganism to mass spectrometry; and acquiring information on Group A Streptococcus of emm type 1, based on the presence or absence, or magnitude of a peak in a first range of m/z of 10930 or more to 10945 or less in the mass spectrum.

An analysis method includes: acquiring data corresponding to a mass spectrum obtained by subjecting a sample containing a microorganism to mass spectrometry; and acquiring information on Group A Streptococcus of emm type 1, based on the presence or absence, or magnitude of a peak in a first range of m/z of 10930 or more to 10945 or less in the mass spectrum.